SG11202111597UA - Methods and compositions for modulating splicing and translation - Google Patents

Methods and compositions for modulating splicing and translation

Info

Publication number
SG11202111597UA
SG11202111597UA SG11202111597UA SG11202111597UA SG11202111597UA SG 11202111597U A SG11202111597U A SG 11202111597UA SG 11202111597U A SG11202111597U A SG 11202111597UA SG 11202111597U A SG11202111597U A SG 11202111597UA SG 11202111597U A SG11202111597U A SG 11202111597UA
Authority
SG
Singapore
Prior art keywords
translation
compositions
methods
modulating splicing
splicing
Prior art date
Application number
SG11202111597UA
Other languages
English (en)
Inventor
Isabel Aznarez
Juergen Scharner
Original Assignee
Stoke Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stoke Therapeutics Inc filed Critical Stoke Therapeutics Inc
Publication of SG11202111597UA publication Critical patent/SG11202111597UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
SG11202111597UA 2019-04-24 2020-04-24 Methods and compositions for modulating splicing and translation SG11202111597UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962838010P 2019-04-24 2019-04-24
PCT/US2020/029897 WO2020219934A1 (en) 2019-04-24 2020-04-24 Methods and compositions for modulating splicing and translation

Publications (1)

Publication Number Publication Date
SG11202111597UA true SG11202111597UA (en) 2021-11-29

Family

ID=72941425

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111597UA SG11202111597UA (en) 2019-04-24 2020-04-24 Methods and compositions for modulating splicing and translation

Country Status (15)

Country Link
US (1) US20220127612A1 (zh)
EP (1) EP3958970A4 (zh)
JP (1) JP2022529532A (zh)
KR (1) KR20220012230A (zh)
CN (1) CN114025848A (zh)
AR (1) AR119722A1 (zh)
AU (1) AU2020262435A1 (zh)
BR (1) BR112021021047A2 (zh)
CA (1) CA3134329A1 (zh)
EA (1) EA202192755A1 (zh)
IL (1) IL287398A (zh)
MX (1) MX2021012989A (zh)
SG (1) SG11202111597UA (zh)
TW (1) TW202106877A (zh)
WO (1) WO2020219934A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
CA3117556A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
CA3166000A1 (en) * 2020-01-28 2021-08-05 Stephen Wilton Antisense oligomers and methods for treating parkin-related pathologies
CN112553328B (zh) * 2020-12-30 2022-06-17 浙江大学 检测基因表达水平的产品及其在制备重度抑郁症诊断工具中的应用
WO2023239782A2 (en) * 2022-06-07 2023-12-14 Kicho Inc. Agents for modulating expression
WO2024009306A1 (en) * 2022-07-07 2024-01-11 Skip Therapeutics Ltd. Compositions and methods for treating primary ciliary dyskinesia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE544473T1 (de) * 2000-11-09 2012-02-15 Cold Spring Harbor Lab Chimäre moleküle zur modulation der genexpression
JP2010507387A (ja) * 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
CA2930859C (en) * 2013-09-04 2022-05-03 Cold Spring Harbor Laboratory Reducing nonsense-mediated mrna decay
EP3265098A4 (en) * 2015-03-03 2019-02-13 Ionis Pharmaceuticals, Inc. COMPOSITIONS FOR MODULATING MECP2 EXPRESSION
JP7170656B2 (ja) * 2017-03-24 2022-11-14 ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ エジンバラ Ｍｅｃｐ２ベースの治療

Also Published As

Publication number Publication date
CN114025848A (zh) 2022-02-08
JP2022529532A (ja) 2022-06-22
BR112021021047A2 (pt) 2022-03-22
CA3134329A1 (en) 2020-10-29
AR119722A1 (es) 2022-01-05
TW202106877A (zh) 2021-02-16
WO2020219934A1 (en) 2020-10-29
EP3958970A1 (en) 2022-03-02
EA202192755A1 (ru) 2022-03-23
MX2021012989A (es) 2022-01-24
KR20220012230A (ko) 2022-02-03
AU2020262435A1 (en) 2021-12-02
EP3958970A4 (en) 2023-05-31
US20220127612A1 (en) 2022-04-28
IL287398A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
ZA202004932B (en) Methods and compositions for modulating splicing
IL287398A (en) Methods and preparations for modulating composition and translation
EP3920918A4 (en) METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING
EP3920917A4 (en) METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING
IL290595A (en) Compositions and methods for modulating protein fusion and expression
EP3920915A4 (en) METHODS AND COMPOSITIONS FOR MODULATING SPLICE
EP3920928A4 (en) METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING
EP3920919A4 (en) METHODS AND COMPOSITIONS FOR MODULATING SPLICE
EP3920916A4 (en) METHODS AND COMPOSITIONS FOR MODULATING SPLICE
EP3920920A4 (en) METHODS AND COMPOSITIONS FOR MODULATING SPLICE
EP3585171A4 (en) COMPOSITIONS AND ASSOCIATED PROCESSES FOR THE MODULATION OF ENDOSYMBIONTES
EP3921311A4 (en) METHODS AND COMPOSITIONS FOR MODULATING SPLICE
EP3920926A4 (en) METHODS AND COMPOSITIONS FOR MODULATING SPLICE
EP3920910A4 (en) METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING
EP3938352A4 (en) METHODS AND COMPOSITIONS FOR MODULATING SPLICE
EP3737390A4 (en) COMPOSITION FOR MODULATING METABOLISM
IL286681A (en) Compounds and methods for modulating ube3a-ats
EP3870206A4 (en) COMPOSITIONS AND METHODS OF MODULATION OF FACTOR VIII FUNCTION
EP3927327A4 (en) METHODS AND DEVICES FOR LOCATING COMPOSITIONS
EP3849564A4 (en) COMPOUNDS AND METHODS FOR MODULATION OF CLN3 EXPRESSION
EP3806840A4 (en) COMPOSITIONS AND METHODS OF MODULATION OF ELOVL2
EP3836941A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUCOSITIS
IL292057A (en) Compositions and methods for inhibiting collagen loss
EP4031155A4 (en) COMPOSITIONS AND METHODS FOR MODULATING THE MICROBIOME
IL307625A (en) Compounds and methods for modulating pnpla3 expression